Featured content
Antibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
ArticleThe global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
ArticleDrug development has changed. Bioanalysis is changing with it
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
ArticleSmall tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.
Opinion and interviews
Physics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
On-demand Webinars
- Previous
- Next
Whitepapers
- Previous
- Next
